Advanced

Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease

Thorsell, Annika; Bjerke, Maria; Gobom, Johan; Brunhage, Eva; Vanmechelen, Eugeen; Andreasen, Niels; Hansson, Oskar LU ; Minthon, Lennart LU ; Zetterberg, Henrik and Blennow, Kaj (2010) In Brain Research1966-01-01+01:00 1362. p.13-22
Abstract
Synaptic pathology occurs early in Alzheimer's disease (AD) development, and cerebrospinal fluid biomarkers for synaptic damage may be altered early in the disease process. In the present study we examined cerebrospinal fluid levels of the postsynaptic protein neurogranin in patients with mild cognitive impairment (MCI) or AD and controls. The low neurogranin level in cerebrospinal fluid required enrichment by immunoprecipitation prior to mass spectrometric identification and semi-quantitative immunoblot analysis. Relative quantification revealed a significant increase of neurogranin in the AD group compared with controls, while the MCI group was not statistically different from either controls or the AD group. The concentrations of the AD... (More)
Synaptic pathology occurs early in Alzheimer's disease (AD) development, and cerebrospinal fluid biomarkers for synaptic damage may be altered early in the disease process. In the present study we examined cerebrospinal fluid levels of the postsynaptic protein neurogranin in patients with mild cognitive impairment (MCI) or AD and controls. The low neurogranin level in cerebrospinal fluid required enrichment by immunoprecipitation prior to mass spectrometric identification and semi-quantitative immunoblot analysis. Relative quantification revealed a significant increase of neurogranin in the AD group compared with controls, while the MCI group was not statistically different from either controls or the AD group. The concentrations of the AD biomarkers T-tau, P-tau(181) and A beta(42) were significantly changed in the control and MCI groups compared with the AD group, but no significant differences were found between the MCI group and controls for the three biomarkers. Nevertheless, a trend towards increasing levels of neurogranin, T-tau and P-tau(181) was found in cerebrospinal fluid from MCI patients compared with controls. The elevated neurogranin levels in the MCI and AD groups might reflect synaptic degeneration. These results together suggest that cerebrospinal fluid neurogranin might be valuable together with the established AD biomarkers in the early diagnosis of AD and warrants further studies to determine the diagnostic value of neuroganin. (C) 2010 Elsevier B.V. All rights reserved. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
impairment, Alzheimer's disease, Mild Cognitive, Synaptic degeneration, Biomarker, Neurogranin
in
Brain Research1966-01-01+01:00
volume
1362
pages
13 - 22
publisher
Elsevier
external identifiers
  • wos:000284667400002
  • scopus:78149362552
ISSN
1872-6240
DOI
10.1016/j.brainres.2010.09.073
language
English
LU publication?
yes
id
f12bc689-4465-449c-a989-fde4e3c98c93 (old id 1752278)
date added to LUP
2011-01-04 07:35:51
date last changed
2018-06-24 03:16:04
@article{f12bc689-4465-449c-a989-fde4e3c98c93,
  abstract     = {Synaptic pathology occurs early in Alzheimer's disease (AD) development, and cerebrospinal fluid biomarkers for synaptic damage may be altered early in the disease process. In the present study we examined cerebrospinal fluid levels of the postsynaptic protein neurogranin in patients with mild cognitive impairment (MCI) or AD and controls. The low neurogranin level in cerebrospinal fluid required enrichment by immunoprecipitation prior to mass spectrometric identification and semi-quantitative immunoblot analysis. Relative quantification revealed a significant increase of neurogranin in the AD group compared with controls, while the MCI group was not statistically different from either controls or the AD group. The concentrations of the AD biomarkers T-tau, P-tau(181) and A beta(42) were significantly changed in the control and MCI groups compared with the AD group, but no significant differences were found between the MCI group and controls for the three biomarkers. Nevertheless, a trend towards increasing levels of neurogranin, T-tau and P-tau(181) was found in cerebrospinal fluid from MCI patients compared with controls. The elevated neurogranin levels in the MCI and AD groups might reflect synaptic degeneration. These results together suggest that cerebrospinal fluid neurogranin might be valuable together with the established AD biomarkers in the early diagnosis of AD and warrants further studies to determine the diagnostic value of neuroganin. (C) 2010 Elsevier B.V. All rights reserved.},
  author       = {Thorsell, Annika and Bjerke, Maria and Gobom, Johan and Brunhage, Eva and Vanmechelen, Eugeen and Andreasen, Niels and Hansson, Oskar and Minthon, Lennart and Zetterberg, Henrik and Blennow, Kaj},
  issn         = {1872-6240},
  keyword      = {impairment,Alzheimer's disease,Mild Cognitive,Synaptic degeneration,Biomarker,Neurogranin},
  language     = {eng},
  pages        = {13--22},
  publisher    = {Elsevier},
  series       = {Brain Research1966-01-01+01:00},
  title        = {Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease},
  url          = {http://dx.doi.org/10.1016/j.brainres.2010.09.073},
  volume       = {1362},
  year         = {2010},
}